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Plasma concentrations of lipoprotein(a) (Lp(a) ), a variant of low density lipoprotein, are determined largely genetically.' A recent review described Lp(a) as "emerging as a major determinant of coronary heart disease."' Impaired glucose tolerance affects around 10% of the population and is associated with an increased likelihood of developing both non-insulin dependent diabetes and coronary artery disease.2 In non-insulin dependent diabetes most of the excess mortality is due to deaths from coronary heart disease, but the reasons are unclear. Associated hypertension, dyslipoproteinaemia, and the recognition of their association with hyperinsulinaemia in "syndrome X" are possible explanations.' As impaired glucose tolerance often precedes non-insulin dependent diabetes we decided to look at concentrations of Lp(a) in these subjects.
Patients, methods, and results
Subjects were identified during a screening programme for diabetes mellitus, in which registered patients aged 45-70 from a local general practice were invited to attend fasting for a 75 g oral glucose tolerance test. Glucose tolerance was classified according to the World Health Organisation's 1985 criteria. Thirty six subjects with impaired glucose tolerance were matched with 36 normal subjects for age (±3 years), sex, and body mass index (+ 2 (weight in kg over square of height in m)). All matched pairs were selected from the same screened population.
Fasting samples were separated within two hours and stored at -70°C. Samples were sent for Lp(a) assay after matching. Lp(a) concentration was measured by Rocket electrophoresis (Immuno; Vienna), the coefficient of variation being 6%. The lower detection limit of the assay was 50 mg/l, values below this being recorded as zero. Serum cholesterol and triglyceride concentrations were determined by an enzymatic method (Boehringer Mannheim, Germany Normal controls and subjects with impaired glucose tolerance did not differ significantly in age (59 3 (7 9) v 59 0 (7-2) years), body mass index (26-6 (3 3) v 27-0 (3-4)), waist to hip ratio (0-88 (0 08) v 0-89 (0 08)), or systolic (144 7 (18-3) v 151 8 (16 9) mm Hg) or diastolic blood pressure (85-1 (9 9) v 89 5 (10-2) mm Hg). The 75th centile for Lp(a) concentrations was significantly higher in subjects with impaired glucose tolerance than in the controls (310 (0-1320) v 110 (0-650) mg/l; p<0 03) (figure). Nine of the 36 subjects with impaired glucose tolerance had Lp(a) values above 300 mg/l compared with two of the normal controls (x2=5 -3; difference in proportions=0 19 (95% confidence interval 0 003 to 0 35); p<003). There were no significant differences between controls and subjects with impaired glucose tolerance in total cholesterol concentration (6-0 (0 98) v 6-4 (0 96) mmol/l), high density lipoprotein cholesterol concentration (1 4 (0-4) v 1-4 (0 36) mmol/1), or low density lipoprotein cholesterol concentration (3-8 (0 9) v 4-0 (0-91) mmol/l). Triglyceride concentration was significantly higher in the subjects with impaired glucose tolerance than in controls (1-8 (0-7-6 0) v 1 4 (0-3-2-8) mmol/l; p<0-001). Patients, methods, and results We studied 15 subjects with active acromegaly (11 men, four women; mean age 50) and 10 nonacromegalic subjects with obstructive sleep apnoea (all men; mean age 51). All subjects gave written informed consent. The data in nine of the acromegalic subjects have been reported.' All 15 acromegalic subjects were treated for a median of 12 months (range 4-32 months) with variable doses of octreotide ranging from 100 to 500 Fg thrice daily subcutaneously. All 10 subjects with sleep apnoea received 100 tg twice daily for two to three months. The results of the sleep study will be reported separately. All subjects had ultrasound examination before beginning octreotide. Seven subjects who formed new gall stones with octreotide were withdrawn from treatment and studied further. At all examinations fasting gall bladder volumes were estimated by the ellipsoid method,4 studies during treatment being performed two hours after the morning injection of octreotide. The presence or absence of gall stones and the gall bladder volume were determined by one of us (GB-W) in a blinded manner. Data are presented as means and standard error of mean (SEM). Paired and unpaired t tests were performed as appropriate.
Gall stones formed in six of the 15 subjects with acromegaly and two of the 10 with sleep apnoea. The combined incidence was therefore 32% (eight of 25 subjects). There was no significant difference in incidence of gall stones between the two groups (X2 analysis). All gall stones were very small (1-2 mm) or small (2-5 mm) and varied in number from a few to the gall bladder being packed with calculi. In seven subjects with new gall stones who were studied up to eight months after withdrawal of octreotide gall stones completely resolved or substantially decreased in number in all but one. In five subjects who had studies available three months after withdrawal gall stone resolution had occurred in only two.
Fasting gall bladder volume was significantly increased during treatment with octreotide. In acromegalic subjects fasting volume increased nearly three- 
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Before Octreotide
Top: Fasting gall bladder volume twO hours after octreotide injection in 13 acromegalic subjects both before and during octreotide treatment and after withdrawal oftreatment in seven subjects. Bottom: Fasting gall bladder volume in nine sleep apnoea subjects both before and during octreotide treatment fold, from 27 (SEM 3) ml to 71 (8) ml (p=0 0002).
(figure), and in sleep apnoea subjects there was also a significant increase, from 30 (4) ml to 50 (6) ml (p=00006) (figure). The baseline and treatment fasting gall bladder volumes were not significantly different between the two groups. There was no significant difference in mean fasting gall bladder volume between subjects who developed gall stones and those who did not. A subgroup of seven acromegalic subjects had studies performed before, during, and after withdrawal of treatment. Fasting gall bladder volume was similarly increased during treatment (27 (3) ml to 63 (7) ml) and reversed to normal after treatment withdrawal (25 (4) ml) (figure).
Comment
This study confirms our observation that long term octreotide increases the risk of cholelithiasis in acromegalic subjects' and shows that this risk extends to a non-acromegalic population, with an overall incidence of 32% (eight to 25 subjects), implying a generalised lithogenic risk with octreotide use. Our study design did not allow us to determine whether dose and duration of treatment were important determinants of gall stone formation.
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